头孢哌酮杂质B | 68779-10-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 头孢哌酮杂质B
• 英文名称: cefoperazone
• 英文别名: (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• CAS: 68779-10-2
• 化学式: C₂₅H₂₇N₉O₈S₂
• 分子量: 645.677
• InChiKey: GCFBRXLSHGKWDP-WTKTZPJXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  44
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  271
• 氢给体数：
  4
• 氢受体数：
  13

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：有限的信息表明，头孢哌酮在乳汁中产生低水平，预计不会对哺乳婴儿造成不良影响。偶尔报道了头孢菌素导致婴儿肠道菌群紊乱，从而引起腹泻或鹅口疮，但这些影响尚未得到充分评估。头孢哌酮在哺乳母亲中是可以接受的。 ◉ 对哺乳婴儿的影响：截至修订日期，未找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，未找到相关的已发布信息。

◉ Summary of Use during Lactation:Limited information indicates cefoperazone produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with cephalosporins, but these effects have not been adequately evaluated. Cefoperazone is acceptable in nursing mothers. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为反应物：
  描述：

  头孢哌酮杂质B 在 silica gel 、 苯甲醚 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 氯仿 为溶剂， 反应 7.0h， 生成 (6R,7R)-7-{2-(4-Carbamoyloxy-phenyl)-2-[(4-ethyl-2,3-dioxo-piperazine-1-carbonyl)-amino]-acetylamino}-3-(1-methyl-1H-tetrazol-5-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  参考文献：
  名称：

  1-Oxacephalosporins: enhancement of .beta.-lactam reactivity and antibacterial activity

  摘要：

  The effect of replacement of sulfur in the cephem nucleus by oxygen upon the beta-lactamase stability, infrared carbonyl frequency of the beta-lactam ring, and antibacterial activity was investigated. The replacement reduced the stability of beta-lactam compounds to beta-lactamases, increased the IR frequencies, and enhanced the intrinsic antibacterial activity against bacterial strains without beta-lactamase. The instability of 1-oxacephalosporins to beta-lactamases, in other words, high reactivity to the enzymes, seemed to be due to the enhanced chemical reactivity of their beta-lactam rings which was indicated by their higher IR beta-lactam carbonyl frequencies. Based on a view that acylation of the enzyme by beta-lactam compounds occurred in both cases of beta-lactamase hydrolysis and target enzyme inhibition, the suggestion was made that one of the factors which conferred the higher intrinsic antibacterial activity on 1-oxacephalosporins was their high reactivity to the target enzyme(s), as was the case with beta-lactamases.

  DOI：

  10.1021/jm00133a018

文献信息

• CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE
  申请人：Cubist Pharmaceuticals, Inc.

  公开号：US20150111853A1

  公开（公告）日：2015-04-23

  Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step.

  本文提供了一种头孢菌素抗生素化合物合成的方法，包括将保护的7-氨基团一步转化为7-羧酰胺基团。
• [EN] CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE<br/>[FR] COMPOSITIONS DE CÉPHALOSPORINE ET PROCÉDÉS DE FABRICATION
  申请人：CUBIST PHARM INC

  公开号：WO2014152763A1

  公开（公告）日：2014-09-25

  Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step.

  本文提供了一种合成头孢菌素抗生素化合物的方法，包括将保护的7-氨基团一步转化为7-羧酰胺基团。
• NAKANISHI, SUSUMU
  作者：NAKANISHI, SUSUMU

  DOI：——

  日期：——
• US20140274958A1
  申请人：——

  公开号：US20140274958A1

  公开（公告）日：2014-09-18
• BORON-BASED PRODRUG STRATEGY FOR INCREASED BIOAVAILABILITY AND LOWER-DOSAGE REQUIREMENTS FOR DRUG MOLECULES CONTAINING AT LEAST ONE PHENOL (OR AROMATIC HYDROXYL) GROUP
  申请人：XAVIER UNIVERSITY OF LOUSIANA

  公开号：US20170137443A1

  公开（公告）日：2017-05-18

  Boron-based prodrugs of phenol- or aromatic hydroxyl group-containing therapeutic molecules (“original drugs”), uses thereof, and methods of making the same, are provided for achieving, for example, improved bioavailability, prolonged retention (e.g., in a circulatory system) and, in particular, significantly lowered therapeutically effective dosage in order to reduce adverse effects while maintaining the desired therapeutic effects of the original drugs.